Get the Stockscreener App
2.39
4.40%
-0.11
After Hours:
2.31
-0.08
-3.35%
Genelux Corp stock is traded at $2.39, with a volume of 321.11K.
It is down -4.40% in the last 24 hours and down -34.34% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$2.50
Open:
$2.48
24h Volume:
321.11K
Relative Volume:
1.43
Market Cap:
$89.87M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-2.5158
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
-22.40%
1M Performance:
-34.34%
6M Performance:
-5.16%
1Y Performance:
-49.47%
1-Day Range:
$2.33
$2.55
1-Week Range:
$2.33
$3.145
52-Week Range:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.39 | 89.87M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com India
HC Wainwright Issues Positive Estimate for Genelux Earnings - MarketBeat
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Yahoo Finance
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener
Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com
Genelux Prices $10.5 Million Stock Offering - MarketScreener
$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline - Stock Titan
Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study - Stock Titan
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - Yahoo Finance
Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D.A. Davidson & CO. Makes New $51,000 Investment in Genelux Co. (NASDAQ:GNLX) - Defense World
Apollon Wealth Management LLC Grows Stock Holdings in Genelux Co. (NASDAQ:GNLX) - Defense World
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - simplywall.st
Genelux Corporation (NASDAQ:GNLX) Announces CFO Transition and Appointment of New CFOGenelux Corporation, a leading biotechnology company, recently disclosed in an SEC filing that Lourie Zak has resigned as Chief Financial Officer, effective imm - Defense World
Genelux Corporation Announces Matt Pulisic Serves as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Genelux appoints new CFO as Lourie Zak departs - MSN
Genelux Corporation Announces New Chief Financial Officer - Markets Insider
Genelux appoints new CFO amid clinical advancements - Investing.com
Genelux Corp. Appoints New CFO Amid Leadership Change - TipRanks
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen - Barchart
Genelux (GNLX) Stock Price, News & Analysis - MarketBeat
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance
Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews
Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux director Tyree James L sells shares worth $8,511 - Investing.com India
Genelux director Tyree James L sells shares worth $8,511 By Investing.com - Investing.com Nigeria
XTX Topco Ltd Invests $59,000 in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux VP sells shares worth $14,742 By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock By Investing.com - Investing.com Australia
Genelux's head of regulatory sells $5,873 in stock By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock - Investing.com
Genelux CEO Zindrick Thomas sells $33,497 in stock - Investing.com
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Yahoo Finance
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):